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ABSTRACT
Aims To summarize evidence on the frequency and predictors of health-care utilization among people who use illicit
drugs. Design Systematic search of MEDLINE, EMBASE and PsychINFO for observational studies reporting health-
care utilization published between 1 January 2000 and 3 December 2018. We conducted narrative synthesis and
meta-analysis following a registered protocol (identiﬁer: CRD42017076525). Setting and participants People who
use heroin, powder cocaine, crack cocaine, methamphetamine, amphetamine, ecstasy/3,4-methylenedioxymethamphet-
amine (MDMA), cannabis, hallucinogens or novel psychoactive substances; have a diagnosis of ‘substance use disorder’; or
use drug treatment services. Measurements Primary outcomes were the cumulative incidence (risk) and rate of care
episodes in three settings: primary care, hospital admissions (in-patient) and emergency department (ED).
Findings Ninety-two studies were included, 84% from North America and Australia. Most studies focused on people
using heroin, methamphetamine or crack cocaine, or who had a diagnosis of drug dependence. We were able to conduct
a meta-analysis of rates across 25 studies reporting ED episodes and 25 reporting hospital admissions, ﬁnding pooled rates
of 151 [95% conﬁdence interval (CI) = 114–201] and 41 (95% CI = 30–57) per 100 person-years, respectively; on aver-
age 4.8 and 7.1 times more often than the general population. Heterogeneity was very high and was not explained by
drugs used, country of study, recruitment setting or demographic characteristics. Predictors of health-care utilization were
consistent across studies and included unstable housing, drug injection and mental health problems. Opioid substitution
therapy was consistently associated with reduced ED presentation and hospital admission. There wasminimal research on
health-care utilization by people using ecstasy/MDMA, powder cocaine, hallucinogens or novel psychoactive substances.
Conclusions People who use illicit drugs are admitted to emergency department or hospital several times more often
than the general population.
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INTRODUCTION
The use of illicit drugs is associated with health, social and
economic problems. People who are dependent on illicit
drugs generally have poor health outcomes, with cohort
studies ﬁndingmortality rates of up to 15 times the general
population, although this varies widely by population and
setting [1,2]. Aswell as overdose, there is excess risk of can-
cers, cardiovascular, respiratory and liver diseases [3–5].
Excess disease may be due to both the direct effects of illicit
drugs and accompanying life circumstances. For instance,
people who use illicit drugs are vulnerable to homelessness,
imprisonment and other forms of social exclusion [6], and
have high rates of tobacco smoking and harmful alcohol
consumption. There are diverse subgroups of people who
use drugs, and people who smoke cannabis or use illicit
drugs occasionally may have better health outcomes than
people who use drugs such as heroin, crack cocaine and
methamphetamine [7,8].
Despite the high need for health care, qualitative re-
search has identiﬁed multiple barriers for people who use
illicit drugs. Health professionals may have negative per-
ceptions of patients who use illicit drugs, including poor
motivation, seeking prescriptions for non-medical purposes
and violent behaviour, and may feel they lack training and
skills to address the needs of this group [9]. Patients report
that staff have stigmatizing attitudes and that there are
barriers to attending appointments, such as transport costs
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and inﬂexible time-slots [10]. People who use drugs may
delay treatment due to normalization of pain, fear of stigma
in services and concern about inadequate opioid substitu-
tion and pain control when admitted to hospital [11].
These barriers mean that symptoms may not be addressed,
leading to presentation late in the course of a disease and
use of emergency care. People who use illicit drugs face dis-
tinct challenges to health-care access related to criminali-
zation and social exclusion. We have therefore chosen to
focus on this group, rather than include people who use al-
cohol, tobacco or other legal drugs.
Studies of patients visiting emergency departments
(ED) have found that 10–20% report recent use of
illicit drugs [12–14], much higher than the general popu-
lation, and diagnoses of drug dependence are common
among frequent ED users [15,16]. Frequent ED users are
particularly likely to use drugs [17]. Such observations
have led to a perception that people who use drugs are re-
liant upon ED services, but there is limited population-
based research into the frequency and patterns of health-
care utilization in this group. We aimed to (1) describe
the frequencies of health-care utilization reported in obser-
vational studies of people who use illicit drugs and calcu-
late pooled averages; (2) compare the frequency of
health-care utilization to the general population; and (3)
summarize evidence on the predictors and causes of
health-care utilization.
METHODS
Review protocol
We conducted a systematic review following the Preferred
Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) guidelines [18]. A protocol for this review has
been registered with PROSPERO (identiﬁer:
CRD42017076525).
Search strategy
We searchedMedline, PsychINFO and EMBASE from1 Jan-
uary 2000 to 27 September 2017 using keywords and
MeSH terms related to substance use, health-care utiliza-
tion and observational study designs (full terms included
in the Supporting information). We also included studies
from a manual search of references. On 3 December
2018 we updated our search, using the same databases,
search terms and inclusion criteria.
Study inclusion and exclusion criteria
We included English-language cohort and cross-sectional
studies where 75% or more of participants had recently
used illicit drugs. Illicit drugs were deﬁned as heroin,
powder cocaine, crack cocaine, methamphetamine,
amphetamine, ecstasy/4-methylenedioxy
methamphetamine (MDMA), cannabis, hallucinogens or
novel psychoactive substances. We also included individ-
uals who had had a diagnosis of ‘substance use disorder’
or were recruited from drug treatment services, where we
were able to determine that at least 75% used illicit drugs
rather than alcohol only. Primary outcomes were the rate
or cumulative incidence of ED episodes, hospital admissions
and primary care presentation.We excluded studies of par-
ticipants recruited from acute health-care services (such as
ED), who had acute disease (such as hepatitis A), whowere
pregnant or were aged less than 18 years. We also ex-
cluded studies with fewer than 30 participants or less than
30 days of observation per participant.
Study quality assessment
Methodological quality was assessed using a modiﬁed
Newcastle-Ottowa scale [19] that included recruitment
bias, non-response, ascertainment of illicit drug use, ascer-
tainment of health-care utilization, adequacy of follow-up
(for cohort studies), selection of comparison groups (for rel-
ative measures) and adjustment (for relative measures).
Full details are given in Supporting information.
Screening and data extraction
Two authors (D.L. and J.F.) independently screened titles
and abstracts using Rayyan [20]. There was agreement
of 94% (Cohen’s kappa 0.58) and conﬂicts were resolved
through discussion. We accessed full texts, and one author
(D.L., J.F. or E.K.) used a piloted data extraction tool to re-
cord details including the study design, year, location of
the study, recruitment setting (drug treatment services,
community or health care), participant demographics, pre-
dominant drugs used and denominator and numerator for
primary outcomes. Where relative frequencies (such as
rate ratios) were reported, we also recorded the ratio and
details of the comparison group. Where predictors of
health-care use and cause-speciﬁc health-care use were re-
ported, we marked the study for narrative synthesis. A sec-
ond author checked that all data was accurate. Queries
that could not be resolved were referred to K.I.M. for a ﬁnal
decision.
Analysis
In a narrative review, we described: (i) the range of
values of the primary outcomes; (ii) predictors of health-
care utilization; and (iii) causes of health-care utilization
by disease.
In quantitative analysis, we displayed frequency rates
of ED and in-patient utilization using forest plots. To
provide informal comparisons with the general population,
we used published frequencies of health-care utilization
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in the United States, Canada, Australia and the
United Kingdom [21–23] for the general population
group with the most similar age and sex proﬁle as the
study population. Details of the comparison group
used for each study are given in the archived data set.
We conducted a random-effects meta-analysis to re-
port the average frequency of health-care utilization
across study populations, limited to results from high-
income countries, and excluded studies of subgroups
likely to have unusual health-care utilization (such as
people living with HIV and prisoners). We anticipated
that the strongest determinants of heterogeneity would
be the predominant drug and the country where the
study was conducted, and therefore stratiﬁed results by
these variables. As an exploratory analysis of further
sources of heterogeneity (not pre-speciﬁed), we included
each of the following variables in the meta-analysis equa-
tion as a moderator [24]: recruitment setting (health
care, drug treatment services, community or prison),
country, study design, study era (1990–99, 2000–09,
2010–18), risk-of-bias score (low or high), age (average
age under or over 30 years) and sex (greater or less than
60% male), using a threshold of P < 0.05 to identify sig-
niﬁcant moderators.
All analysis was conducted using R version 3.5.1.
RESULTS
Search results
Our search identiﬁed 5528 studies after de-duplication,
313 of which were selected for full-text review, and 92
were included. Figure 1 shows a ﬂow-chart of studies.
Some studies included groups from distinct regions or with
distinct drug use patterns, while others duplicated samples
from other studies, and we identiﬁed 98 unique popula-
tions with 204 relevant data points. The full data set is
available in Supporting information.
Description of study populations
Of the 98 study populations, 53 were in the United States;
16 in Australia; 13 in Canada; three in Ireland; two each
in Taiwan, Italy, New Zealand, United Kingdom, Vietnam;
and one each in Denmark, Finland and Norway.
Although the search strategy included people using
any illicit drugs, studies focused on people who used illicit
drugs associated with dependence. The largest group was
people using opiate substitution (31 populations), mainly
recruited from drug treatment services. The next largest
comprised people who inject drugs (29 populations),
mainly recruited from community settings. Eight studies
Figure 1 Flow-chart of included studies
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focused on cannabis users, seven focused on stimulant
users (where injecting was not speciﬁed) and ﬁve focused
on opiate users (where injecting was not speciﬁed).
Figure 2 shows the number of study populations by pre-
dominant drug used and recruitment setting. No studies
recruited participants who predominantly used
MDMA/ecstasy, powder cocaine, novel psychoactive sub-
stances or hallucinogens such as lysergic acid diethylamide
(LSD) and psilocybin.
Amean of 68% [standard deviation (SD) = 12%] of par-
ticipants weremale and themean of average ages (reported
in some studies as means and in others as medians) was
36.7 (SD = 6.0).
Study quality
Fifty-eight of 204 data points had high risk of bias. The
main risk was lack of information on non-response. The
overall risk of bias was not associated with frequency of
health-care utilization in meta-analysis (see below).
Table 1 summarizes results from the quality assessment.
Narrative review
Range of values
Frequencies of all outcomes were high and heterogeneous.
ED utilization ranged from 19 [25] to 1061 [26] per 100
person-years. The proportion of participants visiting ED in
the past 12 months ranged from 10% [27] to 72% [28].
Studies including relative measures showed frequency of
ED utilization of three to 10 times that of comparison
groups not using illicit drugs [29–32]. Exceptions were a
study in rural Taiwan, showing that people who inject
heroin had a similar rate of ED presentation as the general
population [33], and a study of older people who use can-
nabis in the United States showing similar odds of ED pre-
sentation as those who do not use cannabis [34].
The rate of in-patient episodes ranged from 8 [33] to
852 [29] per 100 person-years. The proportion of partici-
pants who were hospitalized during the past 12 months
ranged from 8% [35] to 41% [36]. Studies including rela-
tive measures showed frequency of hospital admission
two to eight times that of comparison groups not using il-
licit drugs [29–31,37–40]. Again, studies of people who in-
ject drugs in rural Taiwan and older people who use
cannabis in the United States were exceptions, showing
similar frequencies of hospital admission to the general
population [33,41].
There were fewer studies of primary care utilization.
Ten studies reported rates, ranging from 231 [42] to
2087 [37] episodes per 100 person-years. The proportion
of participants visiting primary care in the past 12 months
ranged from 38% [43] to 90% [44]. Three studies found a
higher frequency than the general population: a study of
insurance data in Canada found people with diagnoses of
‘substance abuse’ had 4.2 times more primary care visits
than those without this diagnosis [37]; a study of patients
at a specialist primary care clinic in Ireland that found that
thosewithmethadone prescriptions had 4.2 times the odds
of a primary care consultation during 6 months, excluding
visits for drug-related problems [45]; and a study of people
in drug treatment in Australia that found those primarily
in treatment for opioids had a median of 12 primary care
visits in the past year, compared to seven for those in treat-
ment for alcohol [44]. Other studies found a low absolute
frequency of presentation without providing formal
Figure 2 Unique study populations by predominant drug and recruitment source [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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comparisons with the general population. For example,
only 58% of people who inject drugs in Baltimore sawa pri-
mary care doctor over 3 years [46]; 53% of people who use
methamphetamine in Australia saw a primary care doctor
over 12 months [47]; and 32% of people who inject drugs
in Montreal saw a primary care provider over 6 months,
which was informally compared to 90% in the general pop-
ulation [48].
Studies investigating the frequency of health-care utili-
zation in more than one setting showed that primary care
episodes are more frequent than ED or in-patient episodes
[49–53].
Predictors of health-care utilization
ED presentation was consistently associated with regular
or recent injecting [54–57], sex work, [54,58] diagnosed
hepatitis C [40], diagnosed HIV [31,36,56,59,60], female
sex [36,49,61–64], homelessness or unstable housing
[26,55,56,61,65], crack cocaine or stimulant use
[56,61,62], alcohol use [63,66,67], polydrug use [47,68]
and mental health problems [36,37,63].
Hospital admission was associated with similar factors:
regular or recent injecting [55–57,69,70], diagnosed hep-
atitis C [71,72], diagnosed HIV [35,56,69,70,73], low CD4
count among HIV-positive participants [74], female sex
[38,39,49,69,70,72,74], homelessness or unstable hous-
ing [55,69], alcohol use [72], polydrug use [47] and men-
tal health problems [31,37].
One study (the Melbourne Injecting Drug User Cohort
Study) reported similar associations with primary care uti-
lization: regular injecting, homelessness, cocaine injection
and unstable income [48,75].
Opiate substitution treatment was consistently associ-
ated with a lower frequency of ED presentation and hospi-
tal admission [27,36,42,53,57,71,73,76–81] than
comparison groups of untreated opiate users. Among sub-
stitution patients, consistent medication was associated
with a lower rate of ED utilization [77,78,82]. Some studies
looked at different types of treatment. For example, one
study found that take-home methadone was associated
with a lower risk of hospital admission [83]. No studies
looked at the effect of treatment for dependence on drugs
other than opiates.
Some studies reported non-signiﬁcant associationswith
these factors, but none found effects in the opposite
direction.
Although some studies show that mental or physical
morbidity predicts health-care utilization, no studies
attempted to show whether increased frequency of
health-care utilization among people who use illicit drugs
was explained by morbidity or other indicators of need for
services.
Causes of health-care utilization
Studies with cause-speciﬁc data showed that a minority
of ED and in-patient episodes relate to the direct effects of
illicit drugs, such as withdrawal, overdose and intoxication
(Fig. 3). Infections and particularly skin and soft-tissue in-
fections were common causes of ED and in-patient episodes
in study populations in Canada [26,31,54,56,59,69],
Norway [42] and Taiwan [33]. All infections, and
particularly pneumonias, were important causes of
health-care utilization in HIV-positive opiate users
[70,74]. Infections were less important causes of health-
care utilization in Australia [84,85]. Traumas, injuries
and mental health problems were important causes of ED
utilization and hospital admission in all countries
[33,54,56,72,84,85].
Quantitative analysis
We conducted a meta-analysis of health-care utilization
rates (25 studies reporting ED episodes and 25
reporting hospital admission) and 12-month cumulative
incidence (11 studies reporting ED episodes and 11
reporting hospital admission). Twelve months was the
most common period examined in the literature. While
we collected data from studies of other periods, we did not
analyse these data because the periods varied too widely.
We were unable to determine the consistency of the deﬁni-
tion of primary care visits among studies and therefore did
Table 1 Results of quality assessment.
Data points High risk Proportion high risk
Recruitment bias 204 28 14%
Non-response 204 121 59%
Ascertainment of illicit drug use 204 43 21%
Ascertainment of health-care utilization 204 44 22%
Adequacy of follow-up 82 21 26%
Selection of comparison group 47 4 9%
Adjustment for confounders 47 4 9%
Global assessment 204 58 28%
Health service use 5
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not attempt quantitative analysis. We restricted the analy-
sis to populations who primarily use heroin, crack cocaine
or methamphetamine or have a diagnosis of ‘substance
abuse disorder’ or drug dependence, as there were
few studies of people who use cannabis or have other
patterns of use.
ED frequencies are shown in Figs 4 and 5. An average of
29% [95% conﬁdence interval (CI) = 24–35%] of partici-
pants visited ED over a 12-month period. The pooled rate
was 151 visits per 100 person-years (95% CI = 114–
201). There was high heterogeneity, with I2 approaching
100% for both analyses. Thirty-two study populations
were matched with published rates for groups of a similar
age and sex in the general population. ED presentation
ranged from 0.9 to 24.7 times the general population
(mean 4.8). Stratiﬁed meta-analysis by predominant drug
and country did not show signiﬁcant differences to the
overall pooled estimate (see Supporting information), and
the exploratory meta-regression found no signiﬁcant
moderators.
Hospital admission rates and cumulative incidences are
shown in Figs 4 and 5. An average of 22% (95% CI = 15–
31%) of participants were hospitalized over a 12-month pe-
riod. The pooled rate was 41 episodes per 100 person-years
(95% CI = 30–57). There was high heterogeneity, with I2
approaching 100% for both analyses. Twenty-seven
study populations were matched with published rates for
comparable groups in the general population. Hospital ad-
mission rates ranged from 1.9 to 35.5 times the general
population (mean 7.1). As with the ED results, stratiﬁed
meta-analysis by predominant drug and country did not
show signiﬁcant differences to the overall pooled estimate,
and the exploratory meta-regression found no signiﬁcant
moderators.
DISCUSSION
To our knowledge, this is the ﬁrst systematic review of
health-care utilization in people who use illicit drugs. The
majority of available evidence relates to people who use
heroin, methamphetamine and crack cocaine or have a di-
agnosis of drug dependence. The results show high but
widely varying frequencies of ED presentation and hospital
admission in this group.
The pooled frequencies of ED and hospital admissions
are substantially higher than the general population. In
part, this reﬂects morbidity and greater need for treatment.
However, higher utilization does not necessarily represent
good health-care access. A systematic review in 2009
[86] identiﬁed 10 studies showing that people with sub-
stance use disorders are less likely to receive deﬁnitive treat-
ment for speciﬁc conditions, despite higher all-cause
attendance. For example, a study of veterans with diagno-
ses of diabetes in the United States found that participants
with comorbid substance use were less likely to receive foot
or retina examinations [87]. Our ﬁnding of high utilization
of acute services may not represent good access, but a pat-
tern where primary and preventative health care is poor
and unplanned health care is common.
The results contrast with studies of health care among
people who use alcohol, which ﬁnd that drinkers (includ-
ing heavy drinkers) have lower rates of health-care utiliza-
tion than abstainers [88]. This is likely to be explained by
abstention among people who are unwell, rather than a
protective effect of alcohol. In contrast, this review found
that people who use illicit drugs present to health services
much more frequently than the general population. This
may be because studies of people who use illicit drugs tend
to focus on people who are dependent on or use drugs
Figure 3 Main reason for health-care utilization [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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associated with health harms, while studies of alcohol may
include more moderate drinkers.
Predictors of health-care utilization were consistent
across studies, including unstable housing, drug injection
and mental health problems. These factors reﬂect previ-
ously identiﬁed risk factors for poor health in people who
use drugs [89], and are likely to be associated with greater
need for health care.
Effectively, all the variation across studies was due to
differences between populations rather than within-study
error. Despite consistent predictors of health-care utiliza-
tion within studies, we were not able to explain the varia-
tion between studies by the predominant drugs used by
study participants, the country of the study or any other
study-level variables that we collected. Results varied
widely even within countries and populations with appar-
ently similar drug use. For example, in the United States,
the rate of hospital admission of people in opiate substitu-
tion therapy ranged from 51 to 592 per 100 person-years
[53,76–78,90–92]. Other research has conceptualized ac-
cess to health services as a product of individual factors, so-
cial contexts and health-care systems [93,94]. The extent
of the heterogeneity in our results is unlikely to be fully ex-
plained by individual-level factors that we did not capture.
This suggests that social and health-care contexts can sub-
stantially affect health-care utilization. The heterogeneity
also highlights the difﬁculty of generalizing results from
single studies of health-care utilization.
Figure 4 Forest plot of rates of health-care utilization. Studies in grey and italics are not included in the pooled estimate
Health service use 7
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The review identiﬁed three main gaps in the evidence.
First, 84% of study populations were from the United
States, Canada or Australia.We did not identify any studies
from low-income countries. Secondly, there were few stud-
ies with primary care data, even though existing studies
suggest people who use illicit drugs visit primary care more
often than acute health-care settings [49–53], contrary to
the stereotype of reliance on ED. Thirdly, almost all studies
were of people who use heroin, crack cocaine or metham-
phetamine or have a diagnosis of drug dependence. There
were only eight studies of people who use cannabis and
none of people using MDMA/ecstasy, powder cocaine, hal-
lucinogens, novel psychoactive substances or other drugs.
The results highlight the need for interventions that im-
prove general health outcomes among people who use
drugs. Despite a body of research into the effectiveness of
opiate substitutes to reduce use of street heroin [95],
community-distributed naloxone to prevent overdose
deaths [96], strategies to reduce transmission of hepatitis
C and improve access to hepatitis C treatment [97] and
some strategies to improve treatment of soft-tissue infec-
tions among people who inject drugs [98], there is limited
research into interventions that can improve treatment of
health problems that are not speciﬁcally associated with
drug use. Some studies have shown that Housing First
can reduce all-cause ED utilization, although study
outcomes tend to focus on substance use rather than
broader health [99]. Case management (where a single
case manager is assigned to each patient) can improve
drug treatment outcomes but, again, evidence of the effect
on broader health outcomes is limited [100].
Limitations of the evidence
Most studies in the past have described patients in health-
care services to show the proportion that use drugs, rather
than using population-based approaches. This has led in
particular to a focus on ED and frequent healthcare users.
To broaden this focus, we synthesized observational studies
that often report health-care utilization as a secondary out-
come. The strength of this approach is that it has shown
the wide variation in utilization of acute hospital services,
and in some settings primary care may be attended more
frequently. The limitation is that many studies provide lim-
ited insight into predictors and patterns of utilization.
Half the studies in the review (43 of 92) rely on linked
electronic health-care records, which may have inaccura-
cies in diagnostic coding. For example, there is evidence
that drug-related events such as overdoses are under-
recorded in ED data and may be given other diagnostic
codes [101,102]. This could contribute to the small pro-
portion of health-care episodes that are ‘drug-related’ in
Figure 5 Forest plot of 12-month cumulative incidence of health-care utilization. Studies in grey and italics are not included in the pooled estimate
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our results. In addition, few studies include data from the
recent period when synthetic opioids such as fentanyl be-
came more common in North American illicit drug mar-
kets. Opioid-related overdoses in the United States have
increased during this period [103], and the proportion of
health-care episodes that are drug-related may have
increased.
The quality assessment identiﬁed non-response as the
most common problem. This usually resulted from recruit-
ment relying on volunteers or convenience samples rather
than a systematic or random approach. Thesemethods are
often necessary, as it can be difﬁcult to construct sample
frames of people who use drugs. Difﬁculties in constructing
sample frames may also account for the relative lack of
studies of people using some illicit drugs, such as powder
cocaine, although this may also be due to less severe health
outcomes in these groups.
None of the studies included in this review looked at
whether higher morbidity explained higher rates of
health-care use, so we were not able to discuss the appro-
priateness of health service use.
Limitations of the review and meta-analysis
First, we only included English-language studies, which
may partially explain the large proportion of studies from
English-speaking countries—although the English-
language restriction only Excluded 179 of 5528 search re-
sults. Secondly, given the heterogeneity of results, meta-
analysis is only intended to provide an average across stud-
ies, rather than a meaningful estimate of health-care utili-
zation for any speciﬁc population. Thirdly, we deﬁned
health-care utilization with simple rates or proportions.
While this enabled us to perform a traditional systematic
review, it meant that the results provide limited insight into
the appropriateness or equity of the high rates of health-
care utilization that we observed. Finally, our review fo-
cused on three mainstream health-care settings (primary
care, ED and in-patient hospital care), and did not consider
other potential sources of health care such as community
drug treatment services, which sometimes provide a wider
set of interventions. Future research should consider the
full range of health-care provision for people who use
drugs, including opportunities for integration between
drug treatment and mainstream health services.
CONCLUSION
People who use illicit drugs present to acute health
services several times more often than comparison groups
throughout primary care, ED and in-patient settings,
reﬂecting high morbidity. Utilization rates are highest in
those who inject drugs, homeless people and those with
mental health problems. Research is needed into the
quality of health care for people who use illicit drugs, provi-
sion of health care in non-acute settings and the develop-
ment of health services that are considered safe and
acceptable to this group.
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